MAIA Biotechnology, Inc. is a cutting-edge, early stage biotech company, dedicated to developing targeted cancer therapies with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.  A privately-held company based in Chicago, MAIA is led by a passionate, principled and dynamic Management Team with significant drug development experience, committed to advancing promising agents into trials in humans in the next 2-4 years.

MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.